Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) is a global healthcare solutions provider focused on medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. This news page aggregates company announcements, press releases, and other updates related to GE HealthCare’s business activities and capital markets disclosures.
Visitors can find news about GE HealthCare’s collaborations with health systems, governments, and academic institutions, such as agreements to supply advanced CT scanners under national programs, multi-year care alliances with medical centers, and research initiatives in radiation therapy and oncology. The company also issues news on product and technology developments, including imaging systems, AI-powered reconstruction tools, radiology workflow software, and other innovations that it associates with advancing precision care.
GE HealthCare’s news flow includes corporate and investor-focused items as well. Examples include announcements of upcoming earnings releases, participation in healthcare and investor conferences, and responses to shareholder-related matters such as unsolicited mini-tender offers. These communications provide context on how the company presents its strategy, financing activities, and interactions with the capital markets.
Because GE HealthCare emphasizes integrated solutions across Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, many news items highlight how these businesses work together in specific projects or collaborations. Readers can expect coverage of topics such as AI-enabled imaging, diagnostic access initiatives, training and innovation hubs, and alliances aimed at supporting more efficient and precise care. Investors and observers who follow GEHC news can use this page as a centralized view of the company’s publicly released information and developments over time.
GE HealthCare (Nasdaq: GEHC) reported third-quarter 2025 results for the period ended September 30, 2025. Revenues were $5.1 billion, up 6% reported and 4% organic year‑over‑year, with total company orders +6% organic and a book‑to‑bill of 1.06. Net income attributable to GE HealthCare was $446 million; diluted EPS was $0.98 and Adjusted EPS was $1.07. Adjusted EBIT margin was 14.8% and free cash flow was $483 million. The company raised the lower end of full‑year 2025 Adjusted EPS guidance to a range of $4.51 to $4.63 and reaffirmed other metrics while noting approximately $265 million of tariff impact to Adjusted EBIT and $0.45 to Adjusted EPS.
GE HealthCare (Nasdaq: GEHC) announced CE mark clearance for its new Carevance patient monitor on October 21, 2025, enabling initial commercial access in Europe.
Carevance adds Cardiac Output Insights — a non-invasive, on-device hemodynamic view that provides real-time graphical support for perioperative hypotension management without extra hardware or invasive catheters. The platform uses proven algorithms and validated vital-sign parameters and includes the EK-Pro algorithm, which the company says can reduce false ECG alarms by up to 92%. Carevance will be showcased at ESICM in Munich, Oct 25-29, 2025.
GE HealthCare (Nasdaq: GEHC) on October 20, 2025 announced collaborations with The Queen’s Health Systems and Duke Health to co‑develop a new AI‑driven, cloud‑first hospital operations application in its CareIntellect family.
The solution will use predictive analytics to recommend actions across bed demand, staffing, and equipment, drawing on insights from ~500 hospitals (55,000 beds) that use Command Center. Queen’s cited measurable results: 22.2% jump in transfer admissions, 41.2% ED length‑of‑stay reduction, 1.07 day overall LOS drop, and $20M estimated first‑year savings.
GE HealthCare (Nasdaq: GEHC) launched CareIntellect for Perinatal on October 14, 2025, a cloud-first SaaS application built to deliver real-time clinical insights that streamline maternal and fetal care workflows.
The solution integrates uterine activity, blood pressure, fetal heart rate, and maternal SpO2 into a unified chronological view, supports remote monitoring, and runs on a common AWS cloud infrastructure shared across CareIntellect applications for faster deployment, single-sign on, centralized access management, and seamless updates.
Development included clinician input from 29 physicians and 85 nurses across 12 hospitals via a collaboration with HCA Healthcare. GE HealthCare will showcase the product at HLTH 2025 (Oct 19–22).
GE HealthCare (Nasdaq: GEHC) presented University of Michigan findings at ANESTHESIOLOGY 2025 (Oct 10–14) showing End-tidal Control software was associated with lower anesthetic use and emissions in real-world care. The retrospective analysis covered 14,730 adult general anesthesia cases, with End-tidal Control used in 50.5% of cases and active for 82.1% of the maintenance phase. Preliminary results reported reductions of greater than 35% in fresh gas flow, sevoflurane utilization and CO2 emissions during maintenance. The release notes prior GE funding of the study and references additional supporting abstracts and a separate Missouri study with similar lower-flow and cost findings.
GE HealthCare (Nasdaq: GEHC) unveiled Carestation 850, a next-generation anesthesia delivery system with FDA 510(k) pending, following a recent CE mark and approvals in Australia and New Zealand. The system targets perioperative precision with an ergonomic, space-conscious design, continuously optimized algorithms, a widescreen display, refill-while-in-use vaporization and customizable applications for patients from neonates to the elderly. GE HealthCare will showcase Carestation 850 at ANESTHESIOLOGY 2025 (Oct 10–14) at booth #1314. The release cites workforce strain—an estimated 68% of anesthesia professionals at high burnout risk and a projected anesthesiologist shortage of 12,500 by 2033—as drivers for technology adoption and efficiency improvements.
GE HealthCare (Nasdaq: GEHC) has scheduled its third quarter 2025 financial results announcement for October 29, 2025, before market opening. The company's management team will host a conference call and webcast at 8:30 AM ET / 7:30 AM CT on the same day.
Investors can access the live webcast through the company's investor relations website at investor.gehealthcare.com. The earnings release, financial information, and webcast replay will also be available at the same location.
GE HealthCare (Nasdaq: GEHC) has unveiled significant updates to its Intelligent Radiation Therapy (iRT) solution at ASTRO 2025. The AI-supported software aims to revolutionize radiation therapy workflow management, with early adopters reporting reduction in simulation-to-treatment planning time from seven days to seven minutes.
The enhanced iRT features include analytics reporting, staff scheduling, AI-powered organ auto-segmentation, virtual reality patient education, and improved system connectivity. Additionally, GE HealthCare introduced a new iRT capability for theranostics to manage complex workflows in this emerging field.
The solution addresses critical inefficiencies in radiation therapy, which affects 60% of cancer patients but traditionally faces delays of up to 30 days to begin treatment. The company will showcase these innovations along with other radiation oncology solutions at ASTRO 2025 in San Francisco.
GE HealthCare (Nasdaq: GEHC) has announced its quarterly dividend payment. The company's Board of Directors has declared a cash dividend of $0.035 per share for the third quarter of 2025. The dividend will be paid on November 14, 2025, to shareholders of record as of October 24, 2025.
GE HealthCare (Nasdaq: GEHC) has announced plans to acquire icometrix, a Belgian AI-powered brain imaging analysis company, to enhance its neurological care portfolio. The acquisition centers on icometrix's icobrain platform, which includes icobrain aria - the first FDA-cleared AI solution for detecting side effects of Alzheimer's disease amyloid targeting therapies.
The strategic acquisition aims to integrate icometrix's technology with GE HealthCare's MRI systems, enhancing clinical decision support for neurological disorders. icobrain's capabilities extend to analyzing brain MRI scans for conditions including multiple sclerosis, dementia, epilepsy, stroke, and traumatic brain injury. The deal, to be funded with cash on hand, addresses the growing demand for MRI monitoring in Alzheimer's treatment, particularly as the number of adults with the disease is projected to double by 2050.